Improved survival following surgery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database
1 Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, New York, USA
2 Department of Pathology, Roswell Park Cancer Institute, Buffalo, New York, USA
3 Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, New York, USA
4 Department of Head and Neck/Plastic Surgery, Roswell Park Cancer Institute, Buffalo, New York, USA
5 Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
Radiation Oncology 2011, 6:41 doi:10.1186/1748-717X-6-41Published: 25 April 2011
Olfactory Neuroblastoma is a rare malignant tumor of the olfactory tract. Reports in the literature comparing treatment modalities for this tumor are limited.
The SEER database (1973-2006) was queried by diagnosis code to identify patients with Olfactory Neuroblastoma. Kaplan-Meier was used to estimate survival distributions based on treatment modality. Differences in survival distributions were determined by the log-rank test. A Cox multiple regression analysis was then performed using treatment, race, SEER historic stage, sex, age at diagnosis, year at diagnosis and SEER geographic registry.
A total of 511 Olfactory Neuroblastoma cases were reported. Five year overall survival, stratified by treatment modality was: 73% for surgery with radiotherapy, 68% for surgery only, 35% for radiotherapy only, and 26% for neither surgery nor radiotherapy. There was a significant difference in overall survival between the four treatment groups (p < 0.01). At ten years, overall survival stratified by treatment modality and stage, there was no significant improvement in survival with the addition of radiation to surgery.
Best survival results were obtained for surgery with radiotherapy.